TCR T-cell therapy (Juno/Editas)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTCR T-cell therapy (Juno/Editas)

Drug Alias NameTCR therapy (Juno/Editas)Autologous T-cells (Juno/Editas)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionHuman leukocyte antigen modulators

TargetsHuman leukocyte antigen

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesJuno Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEditas Medicine Inc Juno Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A